Daewoong Therapeutics (CEO Bokki Kang), a subsidiary of Daewoong Pharmaceutical, has completed preclinical studies and compiled data for a microneedle patch within the Semaglutide series, a GLP-1 analogue, using its proprietary 'CLOPAM' (Closed-Packed Aeroperssured Microneedle) platform
When blood sugar rises after a meal, GLP-1 amplifies the pancreas's insulin response
This saves time, reduces unnecessary travel, and makes treatment more convenient
However, there are certain conditions, medications, and circumstances when supplements may be needed to meet nutritional needs
In 2016, 1.9 billion adults were classified as overweight and 650 million as obese according to the World Health Organisation in 2016
Out of stock In stock Out of stock There are no reviews yet